PEGylation of interferon alpha 2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases
Lisa M Kaminskas, David B Ascher, Victoria M McLeod, Marco J Herold, Caroline P Le, Erica K Sloan, Christopher JH Porter
Journal of Controlled Release | ELSEVIER | Published : 2013
Awarded by NHMRC
Awarded by NIH
The authors would like to acknowledge funding support by the Samuel Nissen Charitable Foundation (managed by Perpetual Trustees, Australia). LMK was supported by an NHMRC Career Development fellowship. EKS is supported by a National Breast Cancer Foundation fellowship, NIH CA160890 and NHMRC 1008865. This work was supported in part by infrastructure funding from the Victorian Government Operational Infrastructure Support Scheme to St Vincent's Institute.